BANNOCKBURN, Ill. (October 31, 2017)—Option Care Enterprises, Inc., the nation’s largest independent provider of home and alternate treatment site infusion services, has partnered with The ALS Association to offer education, support and enhance the quality of life for idividuals affected by amyotrophic lateral sclerosis (ALS).
With the approval of RADICAVATM (edaravone), the first ALS treatment option approved by the Food and Drug Administration (FDA) in more than 20 years, there’s now an increased need to have access to home infusion services. Option Care is proud to be a nationally contracted home infusion provider of RADICAVATM (edaravone), supporting the ALS community by providing the ability for individuals living with ALS to receive treatment in the comfort of their home. Already, over 100 starts of care have successfully been initiated with RadicavaTM (edaravone). In addition, Option Care provides the industry’s leading nutrition support program and enteral therapy for many individuals living with ALS.
“Option Care applauds The ALS Association’s mission and recognizes their efforts in giving help and hope to those facing the disease,” said John Rademacher, CEO, Option Care. “We look forward to this new partnership with The ALS Association and the ability to be part of providing education, support and services to those living with the disease.”
“We’re deeply grateful for Option Care’s willingness to support our mission of helping people with ALS and their families,” said Calaneet Balas, Executive Vice President of Strategy for The ALS Association. “We’re proud to partner with Option Care as its services are more critical now than ever.”
Visit optioncare.com for more information.
